Background:A Thai weight loss meal replacement brand hopes to add probiotic powder with metabolic regulation function
Formula optimization: Increase the proportion of Akkermansia muciniphila to 20%, and match it with L. plantarum (producing short-chain fatty acids) to form a "fat burning-anti-inflammatory" combination.
Technical support: Provide a composite encapsulation process for strains and meal replacement powders to solve the inactivation problem of meal replacement powders under high-temperature mixing.
1. Formula design ideas and strain function analysis
This composite bacterial powder is composed of 7 strains of highly active probiotics, targeting multi-dimensional needs such as intestinal health, immune regulation, and metabolic support, and improves the comprehensive efficacy through synergistic enhancement. The following is the scientific ratio basis and functional positioning of the core strains:
|
Bacteria species name |
Add Scale |
Core Features |
|
L. plantarum |
20% |
Regulate the balance of intestinal flora, inhibit pathogens, promote nutrient absorption, and relieve inflammatory responses. |
|
B. longum |
18% |
Enhance intestinal barrier function, reduce intestinal permeability, relieve constipation and diarrhea, and regulate immunity. |
|
L. rhamnosus |
15% |
Prevent allergies and infections, lower cholesterol, and improve female urinary and reproductive health. |
|
L. helveticus |
12% |
Breaks down lactose to relieve lactose intolerance; synthesizes bioactive peptides to support the nervous system and mood regulation. |
|
S. thermophilus |
10% |
The production of lactic acid optimizes the intestinal acid environment, promotes the colonization of other probiotics, and assists in the digestion of dairy products. |
|
B. breve |
10% |
Targetedly relieve infant colic, promote the establishment of early intestinal flora, and inhibit the proliferation of pathogenic bacteria. |
|
Akkermansia muciniphila |
15% |
Repair the intestinal mucus layer, improve metabolic syndrome (obesity/diabetes), and enhance immune response (special encapsulation technology is required). |
Formula features:
Covering the entire intestinal niche: Lactobacillus (dominant bacteria in the small intestine) and Bifidobacterium (dominant bacteria in the colon) work together, combined with Akkermansia (mucus layer colonization) to form a three-dimensional protection.
Functional complementation: Digestive support (S. thermophilus) + immune regulation (L. rhamnosus) + metabolic improvement (Akkermansia) multi-target effects.
Popularity: Full coverage from infants (B. breve) to adult metabolic health (Akkermansia).
II. R&D process and technological breakthroughs
Strain screening and compatibility verification
Antagonistic experiment: The 7 strains were verified to have no growth inhibition through in vitro co-culture, and the coexistence stability was determined.
Metabolite analysis: It was found that the peptides secreted by L. helveticus can promote the colonization efficiency of B. longum (increased by about 23%).
Key points of process optimization
Akkermansia muciniphila protection technology: Three-layer embedding (sodium alginate-pectin-chitosan) is used to solve its oxygen sensitivity problem, and the survival rate is increased from 40% to 85%.
Freeze-dried protective agent formula: Add trehalose and sodium glutamate, and the number of live bacteria in the composite bacterial powder stored at room temperature for 6 months decays by less than 10%.
Preclinical efficacy verification
Animal model: In the high-fat diet mouse experiment, the thickness of the intestinal mucus layer in the composite bacterial group increased by 50%, and the serum LPS level decreased by 37%.
In vitro simulated digestion: The performance of gastric acid resistance (survival rate of pH2.5>90%) and bile salt (survival rate of 0.3% concentration>80%) meets the standards.
III. The core role of composite bacterial powder
Multi-dimensional support for intestinal health
Improve diarrhea/constipation/irritable bowel syndrome (IBS);
Repair leaky gut and reduce the risk of endotoxemia.
Metabolism and immune regulation
Regulate blood sugar and blood lipids, assist in obesity intervention (Akkermansia targeted effect);
Reduce allergic reactions and improve vaccine response efficiency.
Application in special populations
Infants and young children: B. breve and L. rhamnosus reduce the incidence of eczema;
Middle-aged and elderly people: B. longum and L. helveticus delay cognitive decline.
IV. Product advantages and innovations
Industry's first new bacteria combination
the first batch of probiotic products in China to industrialize Akkermansia muciniphila.
Precision delivery technology
Differential dissolution and encapsulation technology ensures a colon-targeted release rate of 92%.
Full-process quality control
Complete strain traceability, drug resistance gene detection and allergenicity screening under the ISO22000 system.
V. Application scenarios and customer value
Terminal product form: It can be applied to functional foods (probiotic chewable tablets, yogurt), special medical foods (enteral nutrition preparations), dietary supplements, etc.
Customized service: Support customers to adjust strain ratio as needed (such as focusing on weight loss or immunity), and provide clinical data endorsement.